APA (7th ed.) Citation

Wang, L., Li, J., Xu, D., Fang, J., Van Vollenhoven, R., & Zhang, F. (2023). OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY. Annals of the rheumatic diseases, 82(Suppl 1), 90-91. https://doi.org/10.1136/annrheumdis-2023-eular.1727

Chicago Style (17th ed.) Citation

Wang, L., J. Li, D. Xu, J. Fang, R. Van Vollenhoven, and F. Zhang. "OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY." Annals of the Rheumatic Diseases 82, no. Suppl 1 (2023): 90-91. https://doi.org/10.1136/annrheumdis-2023-eular.1727.

MLA (9th ed.) Citation

Wang, L., et al. "OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY." Annals of the Rheumatic Diseases, vol. 82, no. Suppl 1, 2023, pp. 90-91, https://doi.org/10.1136/annrheumdis-2023-eular.1727.